Статті в журналах з теми "Brand-name pharmaceutical companies"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-42 статей у журналах для дослідження на тему "Brand-name pharmaceutical companies".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Silber, Seth, and Kara Kuritz. "Product Switching in the Pharmaceutical Industry: Ripe for Antitrust Scrutiny?" Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 7, no. 2 (April 2010): 119–30. http://dx.doi.org/10.1057/jgm.2010.1.
Повний текст джерелаXie, Jin, and Joseph Gerakos. "The Anticompetitive Effects of Common Ownership: The Case of Paragraph IV Generic Entry." AEA Papers and Proceedings 110 (May 1, 2020): 569–72. http://dx.doi.org/10.1257/pandp.20201029.
Повний текст джерелаXie, Jin. "Horizontal Shareholdings and Paragraph IV Generic Entry in the U.S. Pharmaceutical Industry." Antitrust Bulletin 66, no. 1 (January 11, 2021): 100–112. http://dx.doi.org/10.1177/0003603x20985797.
Повний текст джерелаFullerton, Thomas M., and Steven L. Fullerton. "Aggregate Online Brand Name Pharmacy Price Dynamics for the United States and Mexico." Economies 10, no. 5 (May 12, 2022): 112. http://dx.doi.org/10.3390/economies10050112.
Повний текст джерелаMoken, Merri C. "Fake Pharmaceuticals: How They and Relevant Legislation or Lack Thereof Contribute to Consistently High and Increasing Drug Prices." American Journal of Law & Medicine 29, no. 4 (2003): 525–42. http://dx.doi.org/10.1017/s0098858800002598.
Повний текст джерелаBoumil, Marcia M., Emily S. Cutrell, Kathleen E. Lowney, and Harris A. Berman. "Pharmaceutical Speakers' Bureaus, Academic Freedom, and the Management of Promotional Speaking at Academic Medical Centers." Journal of Law, Medicine & Ethics 40, no. 2 (2012): 311–25. http://dx.doi.org/10.1111/j.1748-720x.2012.00666.x.
Повний текст джерелаRatheesh, R., Bindu Mohandas, and Bhaskaran K. "Evaluation of drug promotional brochures in a tertiary teaching hospital of Kannur, India." International Journal of Basic & Clinical Pharmacology 7, no. 6 (May 22, 2018): 1089. http://dx.doi.org/10.18203/2319-2003.ijbcp20182051.
Повний текст джерелаScheffer, Mario Cesar. "Interaction between pharmaceutical companies and physicians who prescribe antiretroviral drugs for treating AIDS." Sao Paulo Medical Journal 132, no. 1 (2014): 55–60. http://dx.doi.org/10.1590/1516-3180.2014.1321609.
Повний текст джерелаMalik, Salma, Tejus Anantharamu, M. Fadil Salmani, Sapna Pradhan, and A. G. Mathur. "An analysis of adherence to the World Health Organisation guidelines pertaining to drug promotional literature by pharmaceutical firms." International Journal of Basic & Clinical Pharmacology 7, no. 12 (November 24, 2018): 2429. http://dx.doi.org/10.18203/2319-2003.ijbcp20184860.
Повний текст джерелаLexchin, Joel, Sharon Batt, Devorah Goldberg, and Adrienne Shnier. "National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study." BMJ Open 12, no. 3 (March 2022): e055287. http://dx.doi.org/10.1136/bmjopen-2021-055287.
Повний текст джерелаPonomarova, Olena. "Some aspects of means of individualization on the market of medical and pharmaceutical services." Theory and Practice of Intellectual Property, no. 5 (June 11, 2021): 121–26. http://dx.doi.org/10.33731/52020.233749.
Повний текст джерелаLatif, Ahmed, Muhammad Siddique Ansari, Muhammad Ibrahim Ansari, Rabia Malik, Abdul Ahad Sohoo, Firdous Sohoo, and Umaira Zaib. "Influences of Pharmaceutical Industry on Prescription Practices in Public and Private Hospitals of Islamabad- Pakistan." Pakistan Journal of Public Health 11, no. 1 (May 31, 2021): 24–29. http://dx.doi.org/10.32413/pjph.v11i1.284.
Повний текст джерелаGautam, Sandhya Rani, Preeta Kaur Chugh, Ravinder Kr Sah, and C. D. Tripathi. "Critical appraisal of drug promotional literature using World Health Organisation guidelines." International Journal of Basic & Clinical Pharmacology 6, no. 8 (July 22, 2017): 2014. http://dx.doi.org/10.18203/2319-2003.ijbcp20173289.
Повний текст джерелаVyas, Pratit P., and Amol L. Bhave. "Critical appraisal of Drug Promotional Literatures (DPLs) as per World Health Organization (WHO) guidelines." International Journal of Basic & Clinical Pharmacology 7, no. 2 (January 23, 2018): 238. http://dx.doi.org/10.18203/2319-2003.ijbcp20180092.
Повний текст джерелаLiang, Zhiwen. "Regulatory exclusivity protection for undisclosed test data in China: an innovative approach to implementing the TRIPS Agreement." Queen Mary Journal of Intellectual Property 10, no. 1 (February 19, 2020): 115–27. http://dx.doi.org/10.4337/qmjip.2020.01.05.
Повний текст джерелаIacocca, Kathleen, James Sawhill, and Yao Zhao. "Why brand drugs priced higher than generic equivalents." International Journal of Pharmaceutical and Healthcare Marketing 9, no. 1 (April 7, 2015): 3–19. http://dx.doi.org/10.1108/ijphm-01-2014-0005.
Повний текст джерелаMistry, Vimesh R., Neeta J. Kanani, and Kuntal S. Thacker. "A critical evaluation of promotional drug literatures available with prescribers at a tertiary care teaching hospital in Gujarat, India." International Journal of Basic & Clinical Pharmacology 11, no. 2 (February 23, 2022): 167. http://dx.doi.org/10.18203/2319-2003.ijbcp20220417.
Повний текст джерелаJindal, Meenakshi, Priya Choudhary, and Rajeev K. Sharma. "Analysis of drug promotional literature and its abidance to WHO guidelines." International Journal of Basic & Clinical Pharmacology 8, no. 11 (October 22, 2019): 2502. http://dx.doi.org/10.18203/2319-2003.ijbcp20194792.
Повний текст джерелаHarrop, Chris, John Read, Jim Geekie, and Julia Renton. "An Independent Audit of Pharma Influence in Public Mental Health Trusts in England." Ethical Human Psychology and Psychiatry 20, no. 3 (December 1, 2018): 156–68. http://dx.doi.org/10.1891/1559-4343.20.3.156.
Повний текст джерелаKogan, Lawrence A. "The U.S. Biologics Price Competition and Innovation Act of 2009 Triggers Public Debates, Regulatory/Policy Risks, and International Trade Concerns." Global Trade and Customs Journal 6, Issue 11/12 (November 1, 2011): 513–38. http://dx.doi.org/10.54648/gtcj2011065.
Повний текст джерелаKaras, Laura. "Privacy as the Price of Drug Access." Science and Technology Law Review 23, no. 1 (March 7, 2022): 50–141. http://dx.doi.org/10.52214/stlr.v23i1.9390.
Повний текст джерелаVyas, Noopur, and Savita Shahani. "Analysis of drug promotional literatures in a tertiary care hospital: a cross sectional study." International Journal of Basic & Clinical Pharmacology 8, no. 5 (April 23, 2019): 1102. http://dx.doi.org/10.18203/2319-2003.ijbcp20191608.
Повний текст джерелаMasuda, Sachiko. "The trend in patent infringement litigation against generic drugs or biosimilars in Japan." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 15, no. 1 (January 30, 2019): 10–17. http://dx.doi.org/10.1177/1741134319826338.
Повний текст джерелаSultana, Anwara, Chandona Sorcar, and Mallika Karmaker. "Evaluation of Adherence of Drug Promotional Literatures (DPLs) to World Health Organization Guidelines." Faridpur Medical College Journal 9, no. 2 (November 12, 2015): 88–91. http://dx.doi.org/10.3329/fmcj.v9i2.25682.
Повний текст джерелаAlkadhimi, Akram, Omar T. Dawood, and Mohamed A. Hassali. "Dispensing of antibiotics in community pharmacy in Iraq: a qualitative study." Pharmacy Practice 18, no. 4 (December 12, 2020): 2095. http://dx.doi.org/10.18549/pharmpract.2020.4.2095.
Повний текст джерелаFeldman, Robin. "The Price Tag of "Pay-for-Delay"." Science and Technology Law Review 23, no. 1 (March 7, 2022): 1–49. http://dx.doi.org/10.52214/stlr.v23i1.9389.
Повний текст джерелаVojdani, Aristo, Jama Lambert, and Gottfried Kellermann. "The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III." Evidence-Based Complementary and Alternative Medicine 2011 (2011): 1–11. http://dx.doi.org/10.1093/ecam/nep064.
Повний текст джерелаArora, Malika, Manpreet Kaur, Parveen Bansal, and Manish Arora. "ATC/DDD Directed Classification of Neural Ayurvedic Medicines." Current Traditional Medicine 5, no. 2 (September 23, 2019): 147–58. http://dx.doi.org/10.2174/2215083804666181002093557.
Повний текст джерелаChadha, Alka. "Daiichi Sankyo's generic (mis) adventure: the Ranbaxy takeover." Emerald Emerging Markets Case Studies 2, no. 8 (October 17, 2012): 1–10. http://dx.doi.org/10.1108/20450621211308122.
Повний текст джерелаLi, Xing, and Minyue Jin. "Technology transfer in prescription drug market." Journal of Modelling in Management 13, no. 2 (May 14, 2018): 495–518. http://dx.doi.org/10.1108/jm2-03-2017-0029.
Повний текст джерелаMarcoux, Andrew W. "Information that Brand-Name Companies do not Tell us." Drug Intelligence & Clinical Pharmacy 21, no. 3 (March 1987): 296–97. http://dx.doi.org/10.1177/106002808702100319.
Повний текст джерелаAttri, Rekha. "Anju Pharmaceuticals: riding the herbal wave." Emerald Emerging Markets Case Studies 7, no. 3 (July 24, 2017): 1–26. http://dx.doi.org/10.1108/eemcs-01-2017-0008.
Повний текст джерелаBakker, Andrea. "Is Brand Name Best? Brand name versus generic pharmaceuticals in clinical practice." University of Ottawa Journal of Medicine 7, no. 1 (June 8, 2017). http://dx.doi.org/10.18192/uojm.v7i1.1438.
Повний текст джерелаDaabes, Ajayeb S. Abu, Mohammed Ananzeh, and Faris El-Dahiyat. "Proposing a pharmaceutical brand naming framework based on techniques extracted from decoding current drug names." International journal of health sciences, June 21, 2022. http://dx.doi.org/10.53730/ijhs.v6ns5.9341.
Повний текст джерелаLatwal, Bharti, and Amrish Chandra. "Authorized generics vs. branded generics: A perspective." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, August 3, 2020, 174113432094777. http://dx.doi.org/10.1177/1741134320947773.
Повний текст джерелаByng, Danalyn. "Trade Agreements and Pharmaceutical Patent Protection: Implications for the Governance over Pharmaceutical Products in Canada." Healthy Dialogue 1, no. 1 (September 4, 2012). http://dx.doi.org/10.25071/1929-8404.34702.
Повний текст джерелаBindusha, H. C. "Intellectual Property Rights Issues in Indian Pharmaceutical Industry." Journal of Pharmaceutical Research International, July 28, 2021, 281–86. http://dx.doi.org/10.9734/jpri/2021/v33i38b32124.
Повний текст джерелаNardi, Elene Paltrinieri, and Marcos Bosi Ferraz. "Perception of the value of generic drugs in São Paulo, Brazil." Cadernos de Saúde Pública 32, no. 2 (2016). http://dx.doi.org/10.1590/0102-311x00038715.
Повний текст джерелаHadipour Dehshal, Mahmoud. "Safety and efficacy of drugs: What do I need to know?" Thalassemia Reports 8, no. 1 (April 19, 2018). http://dx.doi.org/10.4081/thal.2018.7494.
Повний текст джерелаPrakash, Gnana. "Perception of rural and urban population on generic and branded drugs." Future Journal of Pharmaceuticals and Health Sciences 1, no. 4 (October 9, 2021). http://dx.doi.org/10.26452/fjphs.v1i4.175.
Повний текст джерелаCarrier, Michael. "Product Hopping." Journal of Commercial Biotechnology 23, no. 2 (August 30, 2017). http://dx.doi.org/10.5912/jcb795.
Повний текст джерелаBhakta, Heran C., Jessica M. Lin, and William H. Grover. "Measuring dissolution profiles of single controlled-release drug pellets." Scientific Reports 10, no. 1 (November 12, 2020). http://dx.doi.org/10.1038/s41598-020-76089-z.
Повний текст джерела